Skip to main content
. Author manuscript; available in PMC: 2017 Sep 11.
Published in final edited form as: Ann Surg. 2010 Sep;252(3):426–433. doi: 10.1097/SLA.0b013e3181f08f32

Table 1.

Characteristics of Patients and Primary Tumors in the 2 Study Arms

Intent-to-Treat Sample Treatment Received Sample
ALND arm
N = 420
SLND only arm
N = 436
ALND
N = 388
SLND only
N = 425
Age, years
  median (min, max) 56(24,92) 54(25,90) 56(24, 92) 54(25, 90)
  missing 7 10 7 10
Age, years
  ≤ 50, no. (%) 135(32.7) 160(37.6) 124 (32.6) 155 (37.4)
  > 50, no. (%) 278(67.3) 266(62.4) 257 (67.4) 260 (62.6)
  missing 7 10 7 10
Clinical T stage, no. (%)
  T1 284(67.9) 303(70.6) 259(67.1) 296(70.5)
  T2 134(32.1) 126(29.4) 127(32.9) 124(29.5)
  missing 2 7 2 5
Clinical tumor size, cm
  median (min, max) 1.7(0.4,7.0) 1.6(0.0,5.0) 1.8 (0.4, 6.0) 1.6 (0, 5.0)
  missing 6 14 6 12
Receptor status, no. (%)
  ER+/PgR+ 256(66.8) 270(68.9) 273(66.8) 264(68.9)
  ER+/PgR− 61(15.9) 54(13.8) 54(15.2) 52(13.6)
  ER−/PgR+ 3(0.8) 4(1.0) 3(0.8) 4(1.0)
  ER−/PgR− 63(16.5) 64(16.3) 61(17.2) 63(16.5)
  missing 37 44 33 42
Estrogen Receptor, no. (%)
  ER+ 327(83.0) 332(83.0) 301(82.2) 323(82.8)
  ER− 67(17.0) 68(17.0) 65(17.8) 67(17.2)
  missing 26 36 22 35
Progesterone Receptor, no. (%)
  PR+ 260(67.7) 274(69.9) 241(67.7) 268(70.0)
  PR− 124(32.3) 118(30.1) 115(32.3) 115(30.0)
  missing 36 44 32 42
LVI*, no. (%)
  Yes 129(40.6) 113(35.2) 124(41.7) 111(35.6)
  No 189(59.4) 208(64.8) 173(58.3) 201(64.4)
  missing 102 115 91 113
Modified Bloom-Richardson score, no (%)
  I 71(22.0) 81(25.6) 64(21.3) 80(26.0)
  II 158(48.9) 148(46.8) 147(49.0) 142(46.3)
  III 94(29.1) 87(27.5) 89(29.7) 85(27.7)
  missing/unknown 97 120 88 118
Tumor type, no. (%)
  Infiltrating ductal 344(82.7) 356(84.0) 317(82.1) 347(84.0)
  Infiltrating lobular 27(6.5) 36(8.5) 25(6.5) 35(8.5)
  Other 45(10.8) 32(7.5) 44(11.4) 31(7.5)
  missing 4 12 2 12
*

LVI, Lymphovascular invasion